PL1656131T3 - Zastosowanie betainy w leczeniu chromania przestankowego - Google Patents

Zastosowanie betainy w leczeniu chromania przestankowego

Info

Publication number
PL1656131T3
PL1656131T3 PL04737684T PL04737684T PL1656131T3 PL 1656131 T3 PL1656131 T3 PL 1656131T3 PL 04737684 T PL04737684 T PL 04737684T PL 04737684 T PL04737684 T PL 04737684T PL 1656131 T3 PL1656131 T3 PL 1656131T3
Authority
PL
Poland
Prior art keywords
treating
betaine
intermittent claudication
describes
arterites
Prior art date
Application number
PL04737684T
Other languages
English (en)
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Publication of PL1656131T3 publication Critical patent/PL1656131T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
PL04737684T 2003-07-15 2004-07-08 Zastosowanie betainy w leczeniu chromania przestankowego PL1656131T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE2003/0408A BE1015608A6 (fr) 2003-07-15 2003-07-15 Traitement des arterites.
PCT/BE2004/000101 WO2005004854A2 (fr) 2003-07-15 2004-07-08 Utilisation de la betaine pour le traitement des arterites
EP04737684A EP1656131B1 (fr) 2003-07-15 2004-07-08 Utilisation de la betaine pour le traitement de la claudication intermittente

Publications (1)

Publication Number Publication Date
PL1656131T3 true PL1656131T3 (pl) 2011-07-29

Family

ID=33569382

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04737684T PL1656131T3 (pl) 2003-07-15 2004-07-08 Zastosowanie betainy w leczeniu chromania przestankowego

Country Status (11)

Country Link
US (2) US8343947B2 (pl)
EP (1) EP1656131B1 (pl)
AT (1) ATE499933T1 (pl)
BE (1) BE1015608A6 (pl)
CA (1) CA2569537A1 (pl)
DE (1) DE602004031631D1 (pl)
DK (1) DK1656131T3 (pl)
ES (1) ES2361915T3 (pl)
PL (1) PL1656131T3 (pl)
PT (1) PT1656131E (pl)
WO (1) WO2005004854A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1013958A6 (fr) * 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
KR20100083820A (ko) * 2007-10-31 2010-07-22 디퓨젼 파마슈티컬즈 엘엘씨 저분자 확산을 촉진시키는 신규한 치료요법
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
RU2523412C1 (ru) * 2013-02-25 2014-07-20 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE644568C (de) * 1934-04-19 1937-05-07 Bristol Aeroplane Co Ltd Kopierfraesmaschine
FR2590M (fr) 1963-03-12 1964-06-15 Albert Beaufour Nouvelles associations antinévralgiques a tolérance améliorée.
US3577534A (en) 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
FR2119889A1 (en) * 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
GB1509979A (en) 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
FR2403799A2 (fr) 1977-09-27 1979-04-20 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
US4605548A (en) 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
DK162986A (da) 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US4902718A (en) 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
EP0347864A3 (en) 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents
IT1226386B (it) 1988-07-08 1991-01-15 Chiesi Farma Spa Procedimento di preparazione di morniflumato e analoghi.
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5405614A (en) 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
WO1995015750A1 (en) * 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
US6355166B1 (en) 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US6056958A (en) 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US5961999A (en) 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
JP3119430B2 (ja) 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
US6162926A (en) 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
LV11727B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
WO1997027829A1 (en) 1996-01-31 1997-08-07 The Trustees Of The University Of Pennsylvania Remote control drug delivery device
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
SE9601395D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
US5880098A (en) 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6258859B1 (en) 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
WO1999045913A1 (en) 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1073432B1 (en) 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
BR9914815A (pt) * 1998-10-30 2001-07-03 Merck Patent Gmbh Composições para tratamento e prevenção de doenças cardiovasculares
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
BE1013958A6 (fr) 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
BE1012546A6 (fr) 1999-03-10 2000-12-05 Messadek Jallal La betaine et ses derives pour leur usage antithrombotique.
DE19910682B4 (de) 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
BE1012712A6 (fr) 1999-06-10 2001-02-06 Messadek Jallal Peptides antithrombotiques.
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
EP1276465B1 (en) * 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
FR2811227A1 (fr) 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
DE10038539A1 (de) 2000-08-03 2002-02-21 Bosch Gmbh Robert Verfahren und Vorrichtung zur energiesparenden Dichtheitsprüfung einer Brennstofftankanlage insbesondere eines Kraftfahrzeuges
MXPA03004458A (es) 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
JP2004515508A (ja) 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
FI114538B (fi) 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
CA2441948A1 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent
US20050020671A1 (en) 2001-02-14 2005-01-27 Matilde Fernandez Ibanez Pharmaceutical formulation
US20040072750A1 (en) 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US6531171B2 (en) 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
US20030054978A1 (en) 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
US20030170223A1 (en) 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20060160896A1 (en) 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
TW200307551A (en) 2002-04-16 2003-12-16 Tanabe Seiyaku Co Phenol compound, process for preparing the same and synthetic intermediate thereof
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
EP1569692B1 (en) 2002-11-25 2010-11-10 Jallal Messadek Betaine and salicylic acid compositions
ES2278314T3 (es) 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
DE10319376B4 (de) 2003-04-30 2007-01-04 Uponor Innovation Ab Pressbacke für ein Presswerkzeug zum Verpressen von Fittingen, Presswerkzeug und Werkzeug zum axialen Aufschieben einer Hülse
US7097968B2 (en) 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
US20060128657A1 (en) 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
CA2575760A1 (en) 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
EP1663174A1 (en) 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
BRPI0510167A (pt) 2004-04-23 2007-10-02 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar
BE1016128A6 (fr) 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen

Also Published As

Publication number Publication date
US20100210608A1 (en) 2010-08-19
DE602004031631D1 (de) 2011-04-14
US8343947B2 (en) 2013-01-01
WO2005004854A2 (fr) 2005-01-20
ATE499933T1 (de) 2011-03-15
DK1656131T3 (da) 2011-06-14
EP1656131A2 (fr) 2006-05-17
WO2005004854A3 (fr) 2005-06-16
CA2569537A1 (fr) 2005-01-20
PT1656131E (pt) 2011-06-07
EP1656131B1 (fr) 2011-03-02
US20130096195A1 (en) 2013-04-18
ES2361915T3 (es) 2011-06-24
BE1015608A6 (fr) 2005-06-07

Similar Documents

Publication Publication Date Title
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2004073614A3 (en) Combination therapy for the treatment of immunoinflammatory disorders
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
AU2003301190A1 (en) Administration of capsaicinoids
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
TW200616644A (en) Medicine for prevention or treatment of diabetes
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA05005437A (es) Nueva combinacion sinergica que comprende roflumilast y formoterol.
SE0102887D0 (sv) New formulation
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
NO20042586L (no) Behandlingsfremgangsmate
DE60235965D1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
TW200610524A (en) Medicine for prevention or treatment of diabetes
TW200608965A (en) Medicine for prevention or treatment of diabetes
WO2006032053A3 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds